The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Treatment-induced mutations in the ligand-binding domain of the androgen receptor (AR) are known to change antagonists into agonists. Recently, the F877L mutation has been described to convert enzalutamide into an agonist. This mutation was seen to co-occur in the endogenous AR allele of LNCaP cells...
Gespeichert in:
Veröffentlicht in: | Molecular cancer therapeutics 2016-07, Vol.15 (7), p.1702-1712 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1712 |
---|---|
container_issue | 7 |
container_start_page | 1702 |
container_title | Molecular cancer therapeutics |
container_volume | 15 |
creator | Prekovic, Stefan van Royen, Martin E Voet, Arnout R D Geverts, Bart Houtman, Rene Melchers, Diana Zhang, Kam Y J Van den Broeck, Thomas Smeets, Elien Spans, Lien Houtsmuller, Adriaan B Joniau, Steven Claessens, Frank Helsen, Christine |
description | Treatment-induced mutations in the ligand-binding domain of the androgen receptor (AR) are known to change antagonists into agonists. Recently, the F877L mutation has been described to convert enzalutamide into an agonist. This mutation was seen to co-occur in the endogenous AR allele of LNCaP cells, next to the T878A mutation. Here, we studied the effects of enzalutamide on the F877L and T878A mutants, as well as the double-mutant AR (F877L/T878A). Molecular modeling revealed favorable structural changes in the double-mutant AR that lead to a decrease in steric clashes for enzalutamide. Ligand-binding assays confirmed that the F877L mutation leads to an increase in relative binding affinity for enzalutamide, but only the combination with the T878A mutation resulted in a strong agonistic activity. This correlated with changes in coregulator recruitment and chromatin interactions. Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR. Mol Cancer Ther; 15(7); 1702-12. ©2016 AACR. |
doi_str_mv | 10.1158/1535-7163.MCT-15-0892 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811894811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1811894811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-ec5943689e8512229a3fe81806d9be67a232f42097b1efa4b08ab068c39b49053</originalsourceid><addsrcrecordid>eNo9kM9PwyAUgInRuDn9EzQcvXTyoxQ4LsumJltMTHcmtH3VmrbU0h70r5e66QXeg--9Bx9Ct5QsKRXqgQouIkkTvtyv04iKiCjNztA8nKtICRqf_8ZHZoauvP8ghAaGXqIZk1QnUiRzdEjfAW_KEvIBuxJvlZQ7bNsCp0qqFd6Pgx0q13rsWrxqi969QYtfIYducH0IfBcuAQ8Ob9pvWwe8qQq4RhelrT3cnPYFOmw36fop2r08Pq9XuyiPhRgiyIWOeaI0hAczxrTlJSiqSFLoDBJpGWdlzIiWGYXSxhlRNiOJyrnOYk0EX6D7Y9-ud58j-ME0lc-hrm0LbvSGKhq-HIc1oOKI5r3zvofSdH3V2P7LUGImo2ayZSZbJhgNmZmMhrq704gxa6D4r_pTyH8AzbpvMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811894811</pqid></control><display><type>article</type><title>The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Prekovic, Stefan ; van Royen, Martin E ; Voet, Arnout R D ; Geverts, Bart ; Houtman, Rene ; Melchers, Diana ; Zhang, Kam Y J ; Van den Broeck, Thomas ; Smeets, Elien ; Spans, Lien ; Houtsmuller, Adriaan B ; Joniau, Steven ; Claessens, Frank ; Helsen, Christine</creator><creatorcontrib>Prekovic, Stefan ; van Royen, Martin E ; Voet, Arnout R D ; Geverts, Bart ; Houtman, Rene ; Melchers, Diana ; Zhang, Kam Y J ; Van den Broeck, Thomas ; Smeets, Elien ; Spans, Lien ; Houtsmuller, Adriaan B ; Joniau, Steven ; Claessens, Frank ; Helsen, Christine</creatorcontrib><description>Treatment-induced mutations in the ligand-binding domain of the androgen receptor (AR) are known to change antagonists into agonists. Recently, the F877L mutation has been described to convert enzalutamide into an agonist. This mutation was seen to co-occur in the endogenous AR allele of LNCaP cells, next to the T878A mutation. Here, we studied the effects of enzalutamide on the F877L and T878A mutants, as well as the double-mutant AR (F877L/T878A). Molecular modeling revealed favorable structural changes in the double-mutant AR that lead to a decrease in steric clashes for enzalutamide. Ligand-binding assays confirmed that the F877L mutation leads to an increase in relative binding affinity for enzalutamide, but only the combination with the T878A mutation resulted in a strong agonistic activity. This correlated with changes in coregulator recruitment and chromatin interactions. Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR. Mol Cancer Ther; 15(7); 1702-12. ©2016 AACR.</description><identifier>ISSN: 1535-7163</identifier><identifier>EISSN: 1538-8514</identifier><identifier>DOI: 10.1158/1535-7163.MCT-15-0892</identifier><identifier>PMID: 27196756</identifier><language>eng</language><publisher>United States</publisher><subject>Amino Acid Substitution ; Androgen Antagonists - pharmacology ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Cell Line, Tumor ; Cluster Analysis ; Codon ; Drug Resistance, Neoplasm - genetics ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Ligands ; Models, Molecular ; Molecular Conformation ; Mutation ; Phenylthiohydantoin - analogs & derivatives ; Phenylthiohydantoin - chemistry ; Phenylthiohydantoin - pharmacology ; Protein Binding ; Receptors, Androgen - chemistry ; Receptors, Androgen - genetics ; Receptors, Androgen - metabolism ; Structure-Activity Relationship ; Transcriptional Activation</subject><ispartof>Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1702-1712</ispartof><rights>2016 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-ec5943689e8512229a3fe81806d9be67a232f42097b1efa4b08ab068c39b49053</citedby><cites>FETCH-LOGICAL-c455t-ec5943689e8512229a3fe81806d9be67a232f42097b1efa4b08ab068c39b49053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27196756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prekovic, Stefan</creatorcontrib><creatorcontrib>van Royen, Martin E</creatorcontrib><creatorcontrib>Voet, Arnout R D</creatorcontrib><creatorcontrib>Geverts, Bart</creatorcontrib><creatorcontrib>Houtman, Rene</creatorcontrib><creatorcontrib>Melchers, Diana</creatorcontrib><creatorcontrib>Zhang, Kam Y J</creatorcontrib><creatorcontrib>Van den Broeck, Thomas</creatorcontrib><creatorcontrib>Smeets, Elien</creatorcontrib><creatorcontrib>Spans, Lien</creatorcontrib><creatorcontrib>Houtsmuller, Adriaan B</creatorcontrib><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Claessens, Frank</creatorcontrib><creatorcontrib>Helsen, Christine</creatorcontrib><title>The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide</title><title>Molecular cancer therapeutics</title><addtitle>Mol Cancer Ther</addtitle><description>Treatment-induced mutations in the ligand-binding domain of the androgen receptor (AR) are known to change antagonists into agonists. Recently, the F877L mutation has been described to convert enzalutamide into an agonist. This mutation was seen to co-occur in the endogenous AR allele of LNCaP cells, next to the T878A mutation. Here, we studied the effects of enzalutamide on the F877L and T878A mutants, as well as the double-mutant AR (F877L/T878A). Molecular modeling revealed favorable structural changes in the double-mutant AR that lead to a decrease in steric clashes for enzalutamide. Ligand-binding assays confirmed that the F877L mutation leads to an increase in relative binding affinity for enzalutamide, but only the combination with the T878A mutation resulted in a strong agonistic activity. This correlated with changes in coregulator recruitment and chromatin interactions. Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR. Mol Cancer Ther; 15(7); 1702-12. ©2016 AACR.</description><subject>Amino Acid Substitution</subject><subject>Androgen Antagonists - pharmacology</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Cluster Analysis</subject><subject>Codon</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Ligands</subject><subject>Models, Molecular</subject><subject>Molecular Conformation</subject><subject>Mutation</subject><subject>Phenylthiohydantoin - analogs & derivatives</subject><subject>Phenylthiohydantoin - chemistry</subject><subject>Phenylthiohydantoin - pharmacology</subject><subject>Protein Binding</subject><subject>Receptors, Androgen - chemistry</subject><subject>Receptors, Androgen - genetics</subject><subject>Receptors, Androgen - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>Transcriptional Activation</subject><issn>1535-7163</issn><issn>1538-8514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM9PwyAUgInRuDn9EzQcvXTyoxQ4LsumJltMTHcmtH3VmrbU0h70r5e66QXeg--9Bx9Ct5QsKRXqgQouIkkTvtyv04iKiCjNztA8nKtICRqf_8ZHZoauvP8ghAaGXqIZk1QnUiRzdEjfAW_KEvIBuxJvlZQ7bNsCp0qqFd6Pgx0q13rsWrxqi969QYtfIYducH0IfBcuAQ8Ob9pvWwe8qQq4RhelrT3cnPYFOmw36fop2r08Pq9XuyiPhRgiyIWOeaI0hAczxrTlJSiqSFLoDBJpGWdlzIiWGYXSxhlRNiOJyrnOYk0EX6D7Y9-ud58j-ME0lc-hrm0LbvSGKhq-HIc1oOKI5r3zvofSdH3V2P7LUGImo2ayZSZbJhgNmZmMhrq704gxa6D4r_pTyH8AzbpvMg</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Prekovic, Stefan</creator><creator>van Royen, Martin E</creator><creator>Voet, Arnout R D</creator><creator>Geverts, Bart</creator><creator>Houtman, Rene</creator><creator>Melchers, Diana</creator><creator>Zhang, Kam Y J</creator><creator>Van den Broeck, Thomas</creator><creator>Smeets, Elien</creator><creator>Spans, Lien</creator><creator>Houtsmuller, Adriaan B</creator><creator>Joniau, Steven</creator><creator>Claessens, Frank</creator><creator>Helsen, Christine</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20160701</creationdate><title>The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide</title><author>Prekovic, Stefan ; van Royen, Martin E ; Voet, Arnout R D ; Geverts, Bart ; Houtman, Rene ; Melchers, Diana ; Zhang, Kam Y J ; Van den Broeck, Thomas ; Smeets, Elien ; Spans, Lien ; Houtsmuller, Adriaan B ; Joniau, Steven ; Claessens, Frank ; Helsen, Christine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-ec5943689e8512229a3fe81806d9be67a232f42097b1efa4b08ab068c39b49053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Amino Acid Substitution</topic><topic>Androgen Antagonists - pharmacology</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Cluster Analysis</topic><topic>Codon</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Ligands</topic><topic>Models, Molecular</topic><topic>Molecular Conformation</topic><topic>Mutation</topic><topic>Phenylthiohydantoin - analogs & derivatives</topic><topic>Phenylthiohydantoin - chemistry</topic><topic>Phenylthiohydantoin - pharmacology</topic><topic>Protein Binding</topic><topic>Receptors, Androgen - chemistry</topic><topic>Receptors, Androgen - genetics</topic><topic>Receptors, Androgen - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>Transcriptional Activation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prekovic, Stefan</creatorcontrib><creatorcontrib>van Royen, Martin E</creatorcontrib><creatorcontrib>Voet, Arnout R D</creatorcontrib><creatorcontrib>Geverts, Bart</creatorcontrib><creatorcontrib>Houtman, Rene</creatorcontrib><creatorcontrib>Melchers, Diana</creatorcontrib><creatorcontrib>Zhang, Kam Y J</creatorcontrib><creatorcontrib>Van den Broeck, Thomas</creatorcontrib><creatorcontrib>Smeets, Elien</creatorcontrib><creatorcontrib>Spans, Lien</creatorcontrib><creatorcontrib>Houtsmuller, Adriaan B</creatorcontrib><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Claessens, Frank</creatorcontrib><creatorcontrib>Helsen, Christine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Molecular cancer therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prekovic, Stefan</au><au>van Royen, Martin E</au><au>Voet, Arnout R D</au><au>Geverts, Bart</au><au>Houtman, Rene</au><au>Melchers, Diana</au><au>Zhang, Kam Y J</au><au>Van den Broeck, Thomas</au><au>Smeets, Elien</au><au>Spans, Lien</au><au>Houtsmuller, Adriaan B</au><au>Joniau, Steven</au><au>Claessens, Frank</au><au>Helsen, Christine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide</atitle><jtitle>Molecular cancer therapeutics</jtitle><addtitle>Mol Cancer Ther</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>15</volume><issue>7</issue><spage>1702</spage><epage>1712</epage><pages>1702-1712</pages><issn>1535-7163</issn><eissn>1538-8514</eissn><abstract>Treatment-induced mutations in the ligand-binding domain of the androgen receptor (AR) are known to change antagonists into agonists. Recently, the F877L mutation has been described to convert enzalutamide into an agonist. This mutation was seen to co-occur in the endogenous AR allele of LNCaP cells, next to the T878A mutation. Here, we studied the effects of enzalutamide on the F877L and T878A mutants, as well as the double-mutant AR (F877L/T878A). Molecular modeling revealed favorable structural changes in the double-mutant AR that lead to a decrease in steric clashes for enzalutamide. Ligand-binding assays confirmed that the F877L mutation leads to an increase in relative binding affinity for enzalutamide, but only the combination with the T878A mutation resulted in a strong agonistic activity. This correlated with changes in coregulator recruitment and chromatin interactions. Our data show that enzalutamide is only a very weak partial agonist of the AR F877L, and a strong partial agonist of the double-mutant AR. Mol Cancer Ther; 15(7); 1702-12. ©2016 AACR.</abstract><cop>United States</cop><pmid>27196756</pmid><doi>10.1158/1535-7163.MCT-15-0892</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1535-7163 |
ispartof | Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1702-1712 |
issn | 1535-7163 1538-8514 |
language | eng |
recordid | cdi_proquest_miscellaneous_1811894811 |
source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
subjects | Amino Acid Substitution Androgen Antagonists - pharmacology Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Cell Line, Tumor Cluster Analysis Codon Drug Resistance, Neoplasm - genetics Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Ligands Models, Molecular Molecular Conformation Mutation Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - chemistry Phenylthiohydantoin - pharmacology Protein Binding Receptors, Androgen - chemistry Receptors, Androgen - genetics Receptors, Androgen - metabolism Structure-Activity Relationship Transcriptional Activation |
title | The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A44%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20F877L%20and%20T878A%20Mutations%20on%20Androgen%20Receptor%20Response%20to%20Enzalutamide&rft.jtitle=Molecular%20cancer%20therapeutics&rft.au=Prekovic,%20Stefan&rft.date=2016-07-01&rft.volume=15&rft.issue=7&rft.spage=1702&rft.epage=1712&rft.pages=1702-1712&rft.issn=1535-7163&rft.eissn=1538-8514&rft_id=info:doi/10.1158/1535-7163.MCT-15-0892&rft_dat=%3Cproquest_cross%3E1811894811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811894811&rft_id=info:pmid/27196756&rfr_iscdi=true |